SS
Saurabh Saha (Director) filed 12 Form 4 reports in the past 24 months (1 purchase, 11 sales), most often in Centessa Pharmaceuticals plc (CNTA). Across 1 priced purchase filing, the average 21-session return was -8.8% from execution and -3.4% from disclosure (delay-adjusted; derived). The largest single filing was $1.6M of CNTA (87,496 sh × $18.46, as filed), executed Dec 6 2024. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-8.8%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-3.4%
same 1 filings, from disclosure
Filings, ttm
12
1 buys · 11 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.4M
shares × price, as filed
Last traded
Jul 21 2025
Filed Jul 21 2025
Median ADV $76.8M across their filed names
Open performance→Volume by month
Buys $254K
Sells $8.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
11 filings
Technology
1 filing
Sector per market data · by filing · past 24 months
Most traded names
CNTA
Centessa Pharmaceuticals plc
CNTA · 0 buys · 11 sells
11 filings
CLVTRecent filings
CNTASALE
Centessa Pharmaceuticals plc
View filing →
$959K55,000 sh × $17.44
Exec Dec 20 2024
Filed Dec 20 2024 · 5:30 PM ET CNTASALE Centessa Pharmaceuticals plc View filing → $1.6M
87,496 sh × $18.46
Exec Dec 6 2024
Filed Dec 6 2024 · 5:30 PM ET CNTASALE Centessa Pharmaceuticals plc View filing → $929K
55,000 sh × $16.89
Exec Nov 20 2024
Filed Nov 22 2024 · 5:30 PM ET CNTASALE Centessa Pharmaceuticals plc View filing → $585K
32,023 sh × $18.28
Exec Nov 13 2024
Filed Nov 15 2024 · 5:30 PM ET